Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Susan R. Goulding"'
Autor:
Jayanth Anantha, Susan R. Goulding, Sean L. Wyatt, Ruth M. Concannon, Louise M. Collins, Aideen M. Sullivan, Gerard W. O'Keeffe
Publikováno v:
iScience, Vol 23, Iss 9, Pp 101457- (2020)
Summary: Loss of midbrain dopaminergic (mDA) neurons and their axons is central to Parkinson's disease (PD). Growth differentiation factor (GDF)5 is a potential neurotrophic factor for PD therapy. However, the molecular mediators of its neurotrophic
Externí odkaz:
https://doaj.org/article/e27b9e83ea704a5f8df395b91d988761
Publikováno v:
Neural Regeneration Research, Vol 17, Iss 1, Pp 38-44 (2022)
Parkinson’s disease is the most common movement disorder worldwide, affecting over 6 million people. It is an age-related disease, occurring in 1% of people over the age of 60, and 3% of the population over 80 years. The disease is characterized by
Externí odkaz:
https://doaj.org/article/fd3a8dcb9f2c4d55b8fe84face25e5bd
Autor:
Martina Mazzocchi, Susan R. Goulding, Noelia Morales-Prieto, Tara Foley, Louise M. Collins, Aideen M. Sullivan, Gerard W. O'Keeffe
Publikováno v:
Brain, behavior, and immunity. 102
Parkinson's disease (PD) is a neurodegenerative disorder characterised by nigrostriatal dopaminergic (DA) neurodegeneration. There is a critical need for neuroprotective therapies, particularly those that do not require direct intracranial administra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f2da5df0472dd4351e87cb0f434481
https://pubmed.ncbi.nlm.nih.gov/35217173
https://pubmed.ncbi.nlm.nih.gov/35217173
Autor:
Jayanth Anantha, Aideen M. Sullivan, Louise M. Collins, Susan R. Goulding, Gerard W. O'Keeffe
Publikováno v:
Neural Regeneration Research
Neural Regeneration Research, Vol 17, Iss 1, Pp 38-44 (2022)
Neural Regeneration Research, Vol 17, Iss 1, Pp 38-44 (2022)
Parkinson’s disease is the most common movement disorder worldwide, affecting over 6 million people. It is an age-related disease, occurring in 1% of people over the age of 60, and 3% of the population over 80 years. The disease is characterized by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5bb097cb253ca5a6c725abeb58434eb
https://pubmed.ncbi.nlm.nih.gov/34100424
https://pubmed.ncbi.nlm.nih.gov/34100424
Autor:
Louise M. Collins, Susan R. Goulding, Gerard W. O'Keeffe, Aideen M. Sullivan, Martina Mazzocchi, Sean Wyatt
Publikováno v:
Molecular and cellular neurosciences. 115
Epigenetic modifications in neurodegenerative disease are under investigation for their roles in disease progression. Alterations in acetylation rates of certain Parkinson's disease (PD)-linked genes have been associated with the pathological progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f96f19482292c85c5b4ef4a37e62bb
https://pubmed.ncbi.nlm.nih.gov/34119632
https://pubmed.ncbi.nlm.nih.gov/34119632
Autor:
Gerard W. O'Keeffe, Gerard Clarke, Sean Wyatt, Martin Lévesque, Louise M. Collins, Susan R. Goulding, Aideen M. Sullivan, Francisca Villalobos-Manriquez, Noelia Morales-Prieto, Ruth M. Concannon
Letter to the Editor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b80fbd486051454923efb54e625f302
Autor:
Gareth Lomansey, Susan R. Goulding, Cathal McCarthy, Adam G. O’Mahony, Jayanth Anantha, Eszter Tuboly, Gerard M. Moloney, Gerard W. O'Keeffe, Louise M. Collins, Aideen M. Sullivan
Publikováno v:
Molecular Neurobiology
Parkinson’s disease (PD) is a neurodegenerative disease characterised by the progressive degeneration of midbrain dopaminergic neurons, coupled with the intracellular accumulation of α-synuclein. Axonal degeneration is a central part of the pathol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b42bb7de6322ac5c5bc916b010470f0
https://pubmed.ncbi.nlm.nih.gov/34623600
https://pubmed.ncbi.nlm.nih.gov/34623600
Autor:
Louise M. Collins, Susan R. Goulding, Martin Lévesque, Gerard W. O'Keeffe, Aideen M. Sullivan
Publikováno v:
Molecular neurobiology. 58(7)
Parkinson's disease is a neurodegenerative disorder characterised by nigrostriatal dopaminergic degeneration, and intracellular a-synuclein aggregation. Current pharmacological treatments are solely symptomatic so there is a need to identify agents t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9f25e23da3d33b40ff1bb683941eef
https://pubmed.ncbi.nlm.nih.gov/33713017
https://pubmed.ncbi.nlm.nih.gov/33713017
Publikováno v:
Neural Regeneration Research
Neural Regeneration Research, Vol 15, Iss 8, Pp 1432-1436 (2020)
Neural Regeneration Research, Vol 15, Iss 8, Pp 1432-1436 (2020)
Parkinson’s disease is the second most common neurodegenerative disorder; it affects 1% of the population over the age of 65. The number of people with Parkinson’s disease is set to rapidly increase due to changing demographics and there is an un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b83028f651787ea07cb6d576af68bb
https://pubmed.ncbi.nlm.nih.gov/31997802
https://pubmed.ncbi.nlm.nih.gov/31997802
Autor:
Gerard W. O'Keeffe, Louise M. Collins, Sean Wyatt, Susan R. Goulding, Aideen M. Sullivan, Jayanth Anantha, Ruth M. Concannon
Publikováno v:
iScience, Vol 23, Iss 9, Pp 101457-(2020)
iScience
iScience
Summary Loss of midbrain dopaminergic (mDA) neurons and their axons is central to Parkinson's disease (PD). Growth differentiation factor (GDF)5 is a potential neurotrophic factor for PD therapy. However, the molecular mediators of its neurotrophic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36421787d853e712e88c02d4ab9d43e4
https://doi.org/10.1016/j.isci.2020.101457
https://doi.org/10.1016/j.isci.2020.101457